Dialysis · Prescription & TechniqueDialysis · Reseta at TeknikDialysis · Reseta ug TeknikDialysis · Reseta at Teknik

Expanded Hemodialysis (HDx): What a Different Filter Can ChangeExpanded Hemodialysis (HDx): Ano ang Kayang Baguhin ng Ibang FilterExpanded Hemodialysis (HDx): Unsa ang Mausab sa Lahi nga FilterExpanded Hemodialysis (HDx): Nanu ing Kayang Bayuan ning Aliwang Filter

Expanded Hemodialysis with Medium Cut-Off and Super High-Flux Membranes

A newer dialysis filter removes more of the larger wastes in your blood. Here is what it may and may not change for you, how the team checks whether it helps, and what to ask about cost.Mas maraming malalaking dumi sa dugo ang naaalis ng mas bagong dialysis filter. Narito kung ano ang maaari at hindi nito mababago para sa iyo, paano susuriin ng team kung nakakatulong ito, at ano ang itatanong tungkol sa gastos.Mas daghang dagkong hugaw sa dugo ang matangtang sa mas bag-o nga dialysis filter. Ania kung unsa ang mahimo ug dili niini mausab alang kanimo, unsaon pagsusi sa team kung makatabang ba kini, ug unsa ang pangutan-on bahin sa gasto.Mas dakal a maragul a dinat king daya ing ilako ning mas bayung dialysis filter. Oyni nung nanu ing malyari at e na mabayuan para keka, makananu yang surian ning team nung tutulung ya, at nanu ing kutnan mu tungkul king gastus.

Rationale, evidence and implementation: membrane physiology, three separate evidence lanes, the albumin trade-off, and a goal-defined pilot for Philippine units.

Summary

Mechanism. Expanded hemodialysis (HDx) uses a medium cut-off (MCO) membrane whose internal filtration removes more large middle molecules than high-flux hemodialysis (HD), with a small, transient fall in serum albumin of about 0.1 g/dL.

Evidence. Randomized trials show greater free light chain removal and suggest less pruritus; one trial suggests slower loss of residual kidney function. A survival benefit is unproven; only high-volume online hemodiafiltration (HDF) has randomized mortality evidence.

Practice. Optimize standard HD, offer high-volume HDF where deliverable, and use HDx as a goal-defined trial with albumin monitoring and a review at about 12 weeks.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 31 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
A Filipino woman in her sixties seated comfortably in a hemodialysis chair, smiling as a nurse holds up a new dialysis filter cartridge for her to see, with soft window light in a calm dialysis unit.

Same machine, same chair — a different filterParehong makina, parehong upuan — ibang filterParehas nga makina, parehas nga lingkuranan — lahi nga filterPareung makina, pareung upuan — aliwang filter

The filter used during dialysis decides which wastes leave your blood. Expanded hemodialysis, often shortened to HDx, uses a newer filter called a medium cut-off (MCO) dialyzer that removes some larger wastes better than the usual filter, while trying to keep the protein your body needs. Your session, machine, chair, and nurses stay the same. Your team can explain what they hope HDx will improve for you, how they will check whether it is working, and whether it changes what you pay.Ang filter na ginagamit sa dialysis ang nagpapasya kung aling dumi ang lalabas sa iyong dugo. Ang expanded hemodialysis, o HDx, ay gumagamit ng mas bagong filter na tinatawag na medium cut-off (MCO) dialyzer na mas mahusay mag-alis ng ilang mas malalaking dumi kaysa sa karaniwang filter, habang sinisikap na panatilihin ang protina na kailangan ng iyong katawan. Pareho pa rin ang iyong session, makina, upuan, at mga nars. Maipapaliwanag ng iyong team kung ano ang inaasahan nilang mapabuti ng HDx sa iyo, paano nila susuriin kung gumagana ito, at kung may epekto ito sa iyong babayaran.Ang filter nga gigamit sa dialysis ang modesisyon kung unsang hugaw ang mogawas sa imong dugo. Ang expanded hemodialysis, o HDx, mogamit og mas bag-o nga filter nga gitawag og medium cut-off (MCO) dialyzer nga mas maayo motangtang sa pipila ka mas dagkong hugaw kaysa sa naandang filter, samtang naningkamot nga tipigan ang protina nga kinahanglan sa imong lawas. Parehas gihapon ang imong session, makina, lingkuranan, ug mga nars. Ikapasabot sa imong team kung unsa ang ilang gilauman nga mapaayo sa HDx kanimo, unsaon nila pagsusi kung molihok ba kini, ug kung makaapekto ba kini sa imong bayronon.Ing filter a gamitan king dialysis ing magpasya nung nanung dinat ing lumual king daya mu. Ing expanded hemodialysis, o HDx, gagamit yang mas bayung filter a aus deng medium cut-off (MCO) dialyzer a mas mayap mamako kareng aliwang mas maragul a dinat nung ing karaniwang filter, kabang pakisanmetung yang panatilian ing protina a kailangan ning katawan mu. Pareu ya pa murin ing session, makina, upuan, at reng nars mu. Apaliwanag na ning team mu nung nanu ing iasa dang mayapan ning HDx keka, makananu deng surian nung gagana ya, at nung atin epektu ya king bayaran mu.

Healthy kidneys filter your blood every minute of the day. They let out waste of many sizes, from tiny molecules such as urea to medium-sized proteins that the body no longer needs, while holding on to large, valuable proteins such as albumin. When the kidneys fail, a dialysis filter (the dialyzer) takes over part of that job. It is a plastic tube packed with thousands of hair-thin hollow fibers. Blood flows inside the fibers; cleaning fluid (dialysate) flows outside them. The fiber walls are full of tiny holes, or pores. Wastes small enough to fit through the pores pass from the blood into the cleaning fluid and are thrown away.Sinasala ng malulusog na bato ang iyong dugo bawat minuto ng araw. Pinalalabas nila ang dumi na iba-iba ang laki, mula sa maliliit na molekula gaya ng urea hanggang sa katamtamang laki na protina na hindi na kailangan ng katawan, habang pinapanatili ang malalaki at mahalagang protina gaya ng albumin. Kapag pumalya ang bato, ang dialysis filter (ang dialyzer) ang umaako sa bahagi ng trabahong iyon. Isa itong plastik na tubo na puno ng libu-libong hollow fiber na kasingnipis ng buhok. Dumadaloy ang dugo sa loob ng mga fiber; dumadaloy naman sa labas ang panlinis na likido (dialysate). Puno ng maliliit na butas, o pores, ang dingding ng mga fiber. Ang mga duming kasya sa mga butas ay lumilipat mula sa dugo papunta sa panlinis na likido at itinatapon.Ginasala sa himsog nga bato ang imong dugo matag minuto sa adlaw. Gipagawas nila ang hugaw nga lain-lain ang gidak-on, gikan sa gagmay nga molekula sama sa urea hangtod sa tunga-tunga nga gidak-on nga protina nga dili na kinahanglan sa lawas, samtang gitipigan ang dagko ug bililhong protina sama sa albumin. Kung mapakyas ang bato, ang dialysis filter (ang dialyzer) ang moako sa bahin niana nga trabaho. Usa kini ka plastik nga tubo nga puno sa linibo ka hollow fiber nga sama kanipis sa buhok. Moagos ang dugo sa sulod sa mga fiber; moagos sa gawas ang panglimpyo nga likido (dialysate). Puno sa gagmay nga lungag, o pores, ang bungbong sa mga fiber. Ang mga hugaw nga kasulod sa mga lungag mobalhin gikan sa dugo ngadto sa panglimpyo nga likido ug ilabay.Salan ning malusug a batu ing daya mu balang minutu king aldo. Paluwalan dang dinat a mikakaiba ing kalagwan, manibat kareng malati a molekula anti ning urea anggang kareng katamtamang protina a e na kailangan ning katawan, kabang panatilian dang ing maragul at mayalagang protina anti ning albumin. Nung mitakman ing batu, ing dialysis filter (ing dialyzer) ing umaku king bage ning obrang ita. Metung yang plastik a tubu a mitmu libu-libung hollow fiber a kasinlati ning buak. Dadaluy ing daya king kilub da reng fiber; dadaluy ya king luwal ing panlinis a likidu (dialysate). Mitmu malating butas, o pores, ing dingding da reng fiber. Ing dinat a kasya kareng butas lilipat ya manibat king daya pakaraya king panlinis a likidu at ibusni ya.

Illustration of a Filipino man in his fifties resting in a hemodialysis chair beside a familiar dialysis machine; a magnified cutaway of the dialyzer shows hollow fibers whose walls have slightly larger, evenly sized pores, letting small and medium waste particles pass into the cleaning fluid while large albumin spheres stay in the blood.

Same chair and machine — only the filter changes. The HDx filter has slightly larger, more even pores, so more medium-sized wastes pass out while most albumin stays in.Parehong upuan at makina — filter lang ang nagbabago. Ang filter ng HDx ay may bahagyang mas malalaki at mas pantay na butas, kaya mas maraming katamtamang laking dumi ang lumalabas habang naiiwan ang karamihan ng albumin.Parehas nga lingkuranan ug makina — filter ra ang mausab. Ang filter sa HDx adunay gamay nga mas dagko ug mas parehas nga lungag, mao nga mas daghang tunga-tunga nga hugaw ang mogawas samtang mabilin ang kadaghanan sa albumin.Pareung upuan at makina — filter mu ing mibayu. Ing filter ning HDx atin yang kaunting mas maragul at mas pantay a butas, anya mas dakal a katamtamang dinat ing lumual kabang mapagkawan ing kayaliwan ning albumin.

HDx
Expanded hemodialysis
MCO
Medium cut-off (dialyzer)

A useful picture is a kitchen strainer. A strainer with holes that are too small keeps back lumps you wanted to remove; holes that are too big let through things you wanted to keep. The HDx filter is designed with pores that are a little larger and more uniform, so that medium-sized wastes pass more easily, while albumin, which is only somewhat larger, mostly stays in the blood. The comparison has limits: a dialysis filter also works by pressure and by the way fluid moves back and forth along the fibers, not only by hole size. That is why your team measures results in your blood instead of assuming them.Isang kapaki-pakinabang na larawan ang salaan sa kusina. Kapag masyadong maliit ang butas, naiiwan ang mga butil na gusto mong alisin; kapag masyadong malaki, nakakalusot ang mga bagay na gusto mong itira. Ang filter ng HDx ay dinisenyo na may mga butas na medyo mas malaki at mas pantay-pantay, kaya mas madaling lumabas ang katamtamang laking dumi, habang ang albumin, na bahagyang mas malaki lamang, ay karaniwang naiiwan sa dugo. May hangganan ang paghahambing: gumagana rin ang dialysis filter sa pamamagitan ng presyon at ng paggalaw ng likido pabalik-balik sa kahabaan ng mga fiber, hindi lang sa laki ng butas. Kaya sinusukat ng iyong team ang resulta sa iyong dugo sa halip na hulaan ito.Usa ka mapuslanon nga hulagway ang salaan sa kusina. Kung gamay kaayo ang lungag, mabilin ang mga bukol nga gusto nimong tangtangon; kung dako kaayo, makalusot ang mga butang nga gusto nimong ibilin. Ang filter sa HDx gidisenyo nga adunay mga lungag nga medyo mas dako ug mas parehas, mao nga mas sayon mogawas ang tunga-tunga nga hugaw, samtang ang albumin, nga gamay ra ang kadak-on, kasagaran mabilin sa dugo. Adunay utlanan ang pagtandi: molihok usab ang dialysis filter pinaagi sa presyon ug sa paglihok sa likido balik-balik subay sa mga fiber, dili lang sa gidak-on sa lungag. Busa sukdon sa imong team ang resulta sa imong dugo imbes nga tagnaon kini.Metung a mayap a larawan ing salaan king kusina. Nung malati ing butas, mapagkawan ing butil a buri mung ilako; nung maragul, makalusut la ring bage a buri mung itagal. Ing filter ning HDx dinisenyu yang atin butas a kaunting mas maragul at mas pantay-pantay, anya mas malagwang lumual ing katamtamang dinat, kabang ing albumin, a kaunti mu ing kayabe kalagwan, karaniwan yang mapagkawan king daya. Atin anggang ing pamanikuat: gagana ya murin ing dialysis filter uli ning presyon at ning pamangalaut ning likidu pabalik-balik king kalabaran da reng fiber, e mu uli ning laki ning butas. Anya sukatan ning team mu ing resulta king daya mu nung e ra pagisipan.

Which wastes the new filter targets — and what it tries to keepAling dumi ang tinatarget ng bagong filter — at ano ang sinisikap nitong itiraUnsang hugaw ang gipunting sa bag-ong filter — ug unsa ang gisulayan niini nga ibilinNanung dinat ing tutuken ning bayung filter — at nanu ing pakisanmetung na itagal

Wastes in the blood come in different sizes, measured in units called daltons. Regular high-flux hemodialysis (HD) is very good at removing small wastes. Medium-sized wastes are harder to remove, and some of them build up over years. The new filter is aimed at the larger end of the medium group.Iba-iba ang laki ng dumi sa dugo, na sinusukat sa yunit na tinatawag na dalton. Napakahusay ng karaniwang high-flux hemodialysis (HD) sa pag-alis ng maliliit na dumi. Mas mahirap alisin ang katamtamang laking dumi, at naiipon ang ilan sa mga ito sa paglipas ng mga taon. Ang bagong filter ay nakatuon sa mas malaking dulo ng katamtamang grupo.Lain-lain ang gidak-on sa hugaw sa dugo, nga gisukod sa yunit nga gitawag og dalton. Maayo kaayo ang naandang high-flux hemodialysis (HD) sa pagtangtang sa gagmay nga hugaw. Mas lisod tangtangon ang tunga-tunga nga hugaw, ug ang pipila niini matigom sa paglabay sa mga tuig. Ang bag-ong filter nagpunting sa mas dakong tumoy sa tunga-tunga nga grupo.Mikakaiba ing kalagwan da reng dinat king daya, a susukatan king yunit a aus deng dalton. Mayap kaya ing karaniwang high-flux hemodialysis (HD) king pamamako kareng malati a dinat. Mas mirap ilako ing katamtamang dinat, at mipupun la reng aliwa kareti kabang miliban ing banwa. Ing bayung filter tutuken ne ing mas maragul a dulu ning katamtamang grupu.

Urea and potassiumUrea at potassiumUrea ug potassiumUrea at potassiumSmallMaliitGamayMalatiRemoved well by both filtersMahusay na naaalis ng dalawang filterMaayo nga matangtang sa duha ka filterMayap a ilako ning adwang filter
β₂-microglobulin (about 12,000 daltons)β₂-microglobulin (mga 12,000 dalton)β₂-microglobulin (mga 12,000 ka dalton)β₂-microglobulin (mga 12,000 dalton)MediumKatamtamanTunga-tungaKatamtamanPartly removed by regular filters; more by HDxBahagyang naaalis ng karaniwang filter; mas marami sa HDxBahin nga matangtang sa naandang filter; mas daghan sa HDxKaunting ilako ning karaniwang filter; mas dakal king HDx
Free light chains and inflammatory proteins (about 22,000–45,000 daltons)Free light chain at mga protina ng pamamaga (mga 22,000–45,000 dalton)Free light chain ug mga protina sa paghubag (mga 22,000–45,000 ka dalton)Free light chain at reng protina ning pamamaga (mga 22,000–45,000 dalton)Large-mediumMalaking katamtamanDako nga tunga-tungaMaragul a katamtamanPoorly removed by regular filters — the main HDx targetMahinang naaalis ng karaniwang filter — pangunahing target ng HDxHuyang nga matangtang sa naandang filter — panguna nga target sa HDxMayina ing pamamako ning karaniwang filter — pangunang tutuken ning HDx
Albumin (about 66,000 daltons)Albumin (mga 66,000 dalton)Albumin (mga 66,000 ka dalton)Albumin (mga 66,000 dalton)Large — keepMalaki — itiraDako — ibilinMaragul — itagalMostly kept by both; HDx lets a little more out, so the team checks your albuminKaraniwang naiiwan sa dalawa; bahagyang mas marami ang nakakalabas sa HDx, kaya sinusuri ng team ang iyong albuminKasagaran mabilin sa duha; gamay nga mas daghan ang makagawas sa HDx, busa susihon sa team ang imong albuminKaraniwan yang mapagkawan king adwa; kaunting mas dakal ing lumual king HDx, anya surian ning team ing albumin mu
Infographic of a size ladder of blood wastes from small urea dots to medium beta-2 microglobulin, larger free light chains and inflammatory proteins, up to large albumin spheres; two sieve bands show the regular high-flux filter letting small wastes pass and the HDx filter also letting larger medium wastes pass, with albumin held back by both.

Wastes from smallest to largest. Both filters remove small wastes well; HDx removes more of the larger medium-sized wastes; both try to keep albumin, the body's main blood protein.Mga dumi mula pinakamaliit hanggang pinakamalaki. Mahusay mag-alis ng maliliit na dumi ang dalawang filter; mas maraming malaking katamtamang dumi ang naaalis ng HDx; parehong sinisikap na itira ang albumin, ang pangunahing protina sa dugo.Mga hugaw gikan sa pinakagamay hangtod sa pinakadako. Maayo motangtang sa gagmay nga hugaw ang duha ka filter; mas daghang dako nga tunga-tunga nga hugaw ang matangtang sa HDx; parehong naningkamot nga ibilin ang albumin, ang panguna nga protina sa dugo.Reng dinat manibat king pekamalati anggang king pekamaragul. Mayap mamako kareng malating dinat ing adwang filter; mas dakal a maragul a katamtamang dinat ing ilako ning HDx; pareu dang pakisanmetung itagal ing albumin, ing pangunang protina king daya.

β₂M
β2-microglobulin
FLC
Free light chains
HDx
Expanded hemodialysis
🔬

Removing more is not the same as feeling betterAng mas maraming naaalis ay hindi pareho ng mas mabuting pakiramdamAng mas daghang matangtang dili parehas sa mas maayong pamatiIng mas dakal a ilako e ya kapareu ning mas mayap a pamakiramdam

Studies clearly show that HDx removes more of these larger wastes during a session. Whether that removal makes people feel better, stay out of the hospital, or live longer is a separate question, and the answers so far are less certain. Your team should not promise a result from a laboratory number alone.Malinaw na ipinapakita ng mga pag-aaral na mas maraming malalaking dumi ang naaalis ng HDx sa isang session. Kung nagpapabuti ba ito ng pakiramdam, nakakaiwas sa ospital, o nagpapahaba ng buhay ay ibang tanong, at hindi pa gaanong tiyak ang mga sagot. Hindi dapat mangako ang iyong team ng resulta batay lamang sa numero sa laboratoryo.Klaro nga gipakita sa mga pagtuon nga mas daghang dagkong hugaw ang matangtang sa HDx sulod sa usa ka session. Kung kini ba makapaayo sa pamati, makalikay sa ospital, o makapalugway sa kinabuhi lahi nga pangutana, ug dili pa kaayo sigurado ang mga tubag. Dili angay mosaad ang imong team og resulta base lang sa numero sa laboratoryo.Malino a ipakit da reng pag-aral a mas dakal a maragul a dinat ing ilako ning HDx king metung a session. Nung pampayap ya ini king pamakiramdam, pamiwas king ospital, o pamaba ning bie aliwang kutang ya, at e pa siguradu ing sagot. E dapat mangaku ing team mu resulta a makabatay mu king numeru ning laboratoryu.

What the research shows, in plain languageAno ang ipinapakita ng pananaliksik, sa simpleng salitaUnsa ang gipakita sa panukiduki, sa yanong pinulonganNanu ing ipakit ning pamanalikmuan, king simpleng amanu

Many people feel no difference after switching. Some report less itching, more energy, or a shorter time to recover after each session; in other studies the two filters scored the same. Here is how strong the evidence is for each hope, from strongest to weakest.Marami ang walang napapansing pagbabago pagkatapos lumipat. May ilang nag-uulat ng mas kaunting kati, mas maraming lakas, o mas maikling panahon ng paggaling pagkatapos ng bawat session; sa ibang pag-aaral, pareho ang marka ng dalawang filter. Narito kung gaano katibay ang ebidensya para sa bawat pag-asa, mula pinakamatibay hanggang pinakamahina.Daghan ang walay mamatikdang kausaban human mobalhin. Ang uban nagtaho og mas gamay nga katol, mas daghang kusog, o mas mubo nga panahon sa pagkaayo human sa matag session; sa ubang pagtuon, parehas ang marka sa duha ka filter. Ania kung unsa kalig-on ang ebidensya alang sa matag paglaum, gikan sa pinakalig-on hangtod sa pinakahuyang.Dakal ing ala mapansin a pamagbayu kaibat dang lumipat. Atin aliwang mamalita a mas kaunti ing kati, mas dakal ing sikan, o mas maikling panaun ning pamanyawa kaibat ning balang session; kareng aliwang pag-aral, pareu ing marka ning adwang filter. Oyni nung nukarin katibe ing ebidensya para king balang pamanasa, manibat king pekamatibe anggang king pekamayina.

Strong evidenceMatibay na ebidensyaLig-on nga ebidensyaMatibe a ebidensya
Removes more larger wastes during each sessionMas maraming malalaking dumi ang naaalis sa bawat sessionMas daghang dagkong hugaw ang matangtang matag sessionMas dakal a maragul a dinat ing ilako king balang session

Shown in many randomized trials. In the main United States trial, one large waste fell by 33% per session with HDx versus 17% with a regular filter.Ipinakita sa maraming randomized trial. Sa pangunahing pag-aaral sa U.S., bumaba ang isang malaking dumi nang 33% kada session sa HDx kumpara sa 17% sa karaniwang filter.Gipakita sa daghang randomized trial. Sa panguna nga pagtuon sa U.S., mius-os ang usa ka dakong hugaw og 33% matag session sa HDx itandi sa 17% sa naandang filter.Ipakit kareng dakal a randomized trial. King pangunang pag-aral king U.S., mibaba ing metung a maragul a dinat 33% balang session king HDx nung ikuat king 17% king karaniwang filter.

Some evidenceMay ilang ebidensyaAdunay pipila ka ebidensyaAtin aliwang ebidensya
Less itching, shorter recovery time, fewer hospital staysMas kaunting kati, mas maikling paggaling, mas kaunting pagpapaospitalMas gamay nga katol, mas mubo nga pagkaayo, mas gamay nga pagpaospitalMas kaunting kati, mas maikling pamanyawa, mas kaunting pamaospital

Seen in small or single studies; not every study agrees. Worth trying only with a clear way to check if it helps you.Nakita sa maliliit o iisang pag-aaral; hindi lahat ng pag-aaral ay sumasang-ayon. Sulit subukan lamang kung may malinaw na paraan para malaman kung nakakatulong ito sa iyo.Nakita sa gagmay o usa ra ka pagtuon; dili tanan nga pagtuon mouyon. Angay sulayan lamang kung adunay klaro nga paagi aron mahibal-an kung makatabang ba kini kanimo.Akit kareng malati o metung mung pag-aral; e ngan ding pag-aral misasabi. Sulit subukan nung atin malinong paralan bang abalu nung tutulung ya keka.

Promising, earlyMay pag-asa, maaga paAdunay paglaum, sayo paAtin pamanasa, maranun pa
Helps protect the kidney function you still haveNakakatulong protektahan ang natitirang gana ng iyong batoMakatabang sa pagpanalipod sa nabilin nga gana sa imong batoTutulung protektan ing kakatagal a gana ning batu mu

One Korean trial of 80 people starting dialysis found slower loss of kidney function over a year. It needs confirmation.Isang pag-aaral sa Korea sa 80 taong nagsisimula ng dialysis ang nakakitang mas mabagal ang pagkawala ng gana ng bato sa loob ng isang taon. Kailangan pa itong kumpirmahin.Usa ka pagtuon sa Korea sa 80 ka tawo nga nagsugod og dialysis ang nakakita nga mas hinay ang pagkawala sa gana sa bato sulod sa usa ka tuig. Kinahanglan pa kini kumpirmahon.Metung a pag-aral king Korea kareng 80 a taung mumpisa dialysis ing akakit a mas dahan ing pamanyalang ning gana ning batu king kilub ning metung a banwa. Kailangan pa yang kumpirman.

Not yet provenHindi pa napapatunayanWala pa mapamatud-iE pa mapatune
Helps people live longerNagpapahaba ng buhayMakapalugway sa kinabuhiPampaba ning bie

Only observational studies suggest this, and they can be misleading. A large trial in Canada, DIALEX (DIALysis with EXpanded solute removal), is testing it now, with results expected around 2030.Mga obserbasyonal na pag-aaral lamang ang nagmumungkahi nito, at maaari silang makalinlang. Isang malaking pag-aaral sa Canada, ang DIALEX (DIALysis with EXpanded solute removal), ang sumusubok nito ngayon, at inaasahan ang resulta bandang 2030.Mga obserbasyonal nga pagtuon lamang ang nagsugyot niini, ug mahimo silang makapahisalaag. Usa ka dakong pagtuon sa Canada, ang DIALEX (DIALysis with EXpanded solute removal), ang nagsulay niini karon, ug gilauman ang resulta mga 2030.Obserbasyonal mung pag-aral ing mamyalung kaniti, at malyari lang makapalinlang. Metung a maragul a pag-aral king Canada, ing DIALEX (DIALysis with EXpanded solute removal), ing susubuk kaniti ngeni, at iasa ing resulta mga 2030.

Four-step evidence staircase infographic for patients: a solid green step for removing more larger wastes, a teal step for possible symptom relief such as less itching and faster recovery, an amber dotted step for protecting remaining kidney function, and a gray outlined step marked with a question mark for living longer, each with a simple icon.

How sure are we? Removing more large wastes is well proven. Symptom relief and fewer hospital stays have some support. Protecting kidney function is promising. Living longer is not yet proven.Gaano tayo kasigurado? Matibay na napatunayan ang pag-alis ng mas maraming malalaking dumi. May ilang suporta ang ginhawa sa sintomas at mas kaunting pagpapaospital. May pag-asa ang pagprotekta sa gana ng bato. Hindi pa napapatunayan ang mas mahabang buhay.Unsa ka sigurado kita? Lig-on nga napamatud-an ang pagtangtang sa mas daghang dagkong hugaw. Adunay pipila ka suporta ang kahupay sa sintomas ug mas gamay nga pagpaospital. Adunay paglaum ang pagpanalipod sa gana sa bato. Wala pa mapamatud-i ang mas taas nga kinabuhi.Nukarin tamu kasiguradu? Matibe a mepatune ing pamamako mas dakal a maragul a dinat. Atin aliwang suporta ing ginawa king sintomas at mas kaunting pamaospital. Atin pamanasa ing pamprotekta king gana ning batu. E pa mapatune ing mas mabayang bie.

Before switching, it helps to name one thing that matters to you, such as itching at night, feeling drained for the rest of the day after dialysis, or trouble sleeping. Tell your team when it happens and what it stops you from doing. Then you and the team can score it the same way before and after the change, so you both know whether the new filter is worth keeping.Bago lumipat, makakatulong na pangalanan ang isang bagay na mahalaga sa iyo, gaya ng pangangati sa gabi, pagkapagod sa buong araw pagkatapos ng dialysis, o hirap matulog. Sabihin sa iyong team kung kailan ito nangyayari at kung ano ang hindi mo nagagawa dahil dito. Pagkatapos, maaari ninyo itong markahan sa parehong paraan bago at pagkatapos ng pagbabago, upang pareho ninyong malaman kung sulit bang ituloy ang bagong filter.Sa dili pa mobalhin, makatabang nga nganlan ang usa ka butang nga importante kanimo, sama sa pagkatol sa gabii, kakapoy sa tibuok adlaw human sa dialysis, o kalisod sa pagkatulog. Isulti sa imong team kung kanus-a kini mahitabo ug unsa ang dili nimo mabuhat tungod niini. Unya, mamarkahan ninyo kini sa parehas nga paagi sa wala pa ug human sa kausaban, aron pareho ninyong mahibal-an kung angay ba ipadayon ang bag-ong filter.Bayu ka lumipat, makatulung nung lagyu me ing metung a bage a mayalaga keka, anti ning kati king bengi, kapagal king kabilugan ning aldo kaibat ning dialysis, o mirap matudtud. Sabyan me king team mu nung kapilan ya mamaliari at nanu ing e mu agawa uli na niti. Kaibat na, malyari yu yang markan king pareung paralan bayu at kaibat ning pamagbayu, bang pareu yung abalu nung sulit ya ituloy ing bayung filter.

Albumin: the protein the team keeps an eye onAlbumin: ang protina na binabantayan ng teamAlbumin: ang protina nga ginabantayan sa teamAlbumin: ing protina a babantayan ning team

Albumin is the most common protein in your blood. It is made by the liver from the protein you eat, and it helps hold water inside the blood vessels and carry medicines and hormones. Because the HDx filter has slightly larger pores, a little more albumin can leave during each session. In the studies, blood albumin dipped slightly in the first months on average and then usually settled back; it did not fall dangerously in the trials. Still, every person is different, so the team checks it.Ang albumin ang pinakakaraniwang protina sa iyong dugo. Ginagawa ito ng atay mula sa protina na iyong kinakain, at tumutulong ito na panatilihin ang tubig sa loob ng mga ugat at magdala ng gamot at hormone. Dahil bahagyang mas malaki ang butas ng filter ng HDx, bahagyang mas maraming albumin ang maaaring lumabas sa bawat session. Sa mga pag-aaral, bahagyang bumaba ang albumin sa unang mga buwan sa karaniwan at kadalasang bumabalik pagkatapos; hindi ito bumaba nang mapanganib sa mga pag-aaral. Gayunpaman, magkakaiba ang bawat tao, kaya sinusuri ito ng team.Ang albumin mao ang labing komon nga protina sa imong dugo. Gihimo kini sa atay gikan sa protina nga imong gikaon, ug motabang kini sa pagpabilin sa tubig sulod sa mga ugat ug sa pagdala sa tambal ug hormone. Tungod kay gamay nga mas dako ang lungag sa filter sa HDx, gamay nga mas daghang albumin ang mahimong mogawas matag session. Sa mga pagtuon, gamay nga mius-os ang albumin sa unang mga bulan sa kasagaran ug kasagaran mobalik human niini; wala kini mius-os sa makuyaw nga paagi sa mga pagtuon. Bisan pa niana, lahi-lahi ang matag tawo, busa susihon kini sa team.Ing albumin ya ing pekakaraniwang protina king daya mu. Gawan ne ning ati manibat king protina a pamangan mu, at tutulung ya bang panatilian ing danum king kilub da reng uyat at mangawit gamut at hormone. Uling kaunting mas maragul ing butas ning filter ning HDx, kaunting mas dakal a albumin ing malyaring lumual king balang session. Kareng pag-aral, kaunti yang mibaba ing albumin kareng mumuna a bulan king karaniwan at karaniwan yang mibalik kaibat; e ya mibaba king mapanganib a paralan kareng pag-aral. Oneng, mikakaiba ing balang tau, anya surian ne ning team.

A lower albumin result does not automatically mean the filter is to blame. Albumin also falls with infection or inflammation, extra body water, poor appetite, recent hospital stays, and protein loss in urine. That is why the team looks at the trend over several tests, alongside your appetite, weight, and recent illness, before deciding anything. Eating enough protein, as your dietitian advises, matters on any filter.Ang mas mababang resulta ng albumin ay hindi agad nangangahulugang filter ang may kasalanan. Bumababa rin ang albumin dahil sa impeksyon o pamamaga, sobrang tubig sa katawan, mahinang gana sa pagkain, kamakailang pagpapaospital, at pagkawala ng protina sa ihi. Kaya tinitingnan ng team ang takbo sa ilang test, kasama ang iyong gana, timbang, at kamakailang sakit, bago magpasya. Mahalaga ang sapat na pagkain ng protina, ayon sa payo ng iyong dietitian, sa anumang filter.Ang mas ubos nga resulta sa albumin dili dayon nagpasabot nga ang filter ang sad-an. Mius-os usab ang albumin tungod sa impeksyon o paghubag, sobrang tubig sa lawas, huyang nga gana sa pagkaon, bag-o lang nga pagpaospital, ug pagkawala sa protina sa ihi. Busa tan-awon sa team ang dagan sa pipila ka test, uban ang imong gana, timbang, ug bag-ong sakit, sa dili pa modesisyon. Importante ang igo nga pagkaon og protina, sumala sa tambag sa imong dietitian, sa bisan unsang filter.Ing mas mababang resulta ning albumin e ya agad mamakabaldugan a ing filter ing atin kasalanan. Babamba ya murin ing albumin uli ning impeksyon o pamamaga, sobrang danum king katawan, mayinang gana king pamangan, bayu-bayung pamaospital, at pamanyalang protina king ini. Anya lawan ning team ing takbu kareng aliwang test, kayabe ing gana mu, timbang, at bayung sakit, bayu magpasya. Mayalaga ing sapat a pamangan protina, agpang king payu ning dietitian mu, king nanumang filter.

Regular HD, HDx, and online HDF side by sideKaraniwang HD, HDx, at online HDF magkatabiNaandang HD, HDx, ug online HDF magkatupadKaraniwang HD, HDx, at online HDF magkasiping

There is a third option some units offer: online hemodiafiltration (HDF). HDF uses a special machine that makes large amounts of ultra-clean replacement fluid during the session, washes extra fluid through the filter, and replaces it. It removes medium-sized wastes by a different route. Unlike HDx, HDF has large trials showing people lived longer when enough fluid was exchanged.May ikatlong opsyon na iniaalok ng ilang unit: ang online hemodiafiltration (HDF). Gumagamit ang HDF ng espesyal na makina na gumagawa ng maraming napakalinis na pamalit na likido sa session, nagpapadaan ng dagdag na likido sa filter, at pinapalitan ito. Inaalis nito ang katamtamang laking dumi sa ibang paraan. Hindi tulad ng HDx, may malalaking pag-aaral ang HDF na nagpapakitang mas tumagal ang buhay ng mga tao kapag sapat ang likidong napalitan.Adunay ikatulong kapilian nga gitanyag sa pipila ka unit: ang online hemodiafiltration (HDF). Mogamit ang HDF og espesyal nga makina nga mohimo og daghang limpyo kaayo nga ilisan nga likido sulod sa session, mopaagi og dugang likido sa filter, ug ilisan kini. Matangtang niini ang tunga-tunga nga hugaw sa laing paagi. Dili sama sa HDx, ang HDF adunay dagkong pagtuon nga nagpakita nga mas milungtad ang kinabuhi sa mga tawo kung igo ang likido nga nailisan.Atin katlung opsyon a ialuk da ring aliwang unit: ing online hemodiafiltration (HDF). Gagamit ya ing HDF espesyal a makina a gagawa dakal a malinis kaya a pamalit a likidu king session, papaliban ne ing dagdag a likidu king filter, at pamalitan ne. Ilako na ing katamtamang dinat king aliwang paralan. E kalupa ning HDx, atin maragul a pag-aral ing HDF a ipakit a mas mibayang bie da reng tau nung sapat ing likidung mepalitan.

FeatureKatangianKinaiyaKatangianRegular high-flux HDKaraniwang high-flux HDNaandang high-flux HDKaraniwang high-flux HDHDxOnline HDFOnline HDFOnline HDFOnline HDF
MachineMakinaMakinaMakinaStandardKaraniwanNaandanKaraniwanStandard (only the filter changes)Karaniwan (filter lang ang iba)Naandan (filter ra ang lahi)Karaniwan (filter mu ing aliwa)Special HDF machine and ultra-clean fluid systemEspesyal na makina ng HDF at sistema ng napakalinis na likidoEspesyal nga makina sa HDF ug sistema sa limpyo kaayo nga likidoEspesyal a makina ning HDF at sistema ning malinis kaya a likidu
Small wastesMaliliit na dumiGagmay nga hugawMalating dinat✓✓✓✓✓✓
Larger medium wastesMalaking katamtamang dumiDako nga tunga-tunga nga hugawMaragul a katamtamang dinat✓✓✓✓✓✓✓
Proof of longer lifePatunay ng mas mahabang buhayPamatuod sa mas taas nga kinabuhiPatune ning mas mabayang bieComparison standardPamantayang paghahambinganSukaranan sa pagtandiPamantayan ning pamanikuatNot yet provenHindi pa napapatunayanWala pa mapamatud-iE pa mapatuneYes, with high exchange volumesOo, sa mataas na dami ng palitanOo, sa taas nga gidaghanon sa ilisanWa, king matas a dakal ning pamalit
Albumin lossPagkawala ng albuminPagkawala sa albuminPamanyalang ning albuminVery lowNapakababaUbos kaayoMababa kayaSlightly higher — checkedBahagyang mas mataas — sinusuriGamay nga mas taas — susihonKaunting mas matas — surianLow to moderate, depends on settingsMababa hanggang katamtaman, depende sa settingUbos hangtod tunga-tunga, depende sa settingMababa anggang katamtaman, depende king setting

Which option fits depends on what your unit can safely provide, your blood vessel access, and your goals. If your center can offer high-volume HDF, ask whether it suits you. If it cannot, HDx may be discussed as a filter change for a specific goal, with a planned review.Kung aling opsyon ang angkop ay depende sa kayang ibigay nang ligtas ng iyong unit, sa iyong access sa ugat, at sa iyong mga layunin. Kung kaya ng iyong center ang high-volume HDF, itanong kung bagay ito sa iyo. Kung hindi, maaaring pag-usapan ang HDx bilang pagpapalit ng filter para sa isang tiyak na layunin, na may nakaplanong pagsusuri.Kung unsang kapilian ang angay depende sa luwas nga mahatag sa imong unit, sa imong access sa ugat, ug sa imong mga tumong. Kung kaya sa imong center ang high-volume HDF, pangutan-a kung haom ba kini kanimo. Kung dili, mahimong hisgotan ang HDx isip pag-ilis sa filter alang sa usa ka piho nga tumong, nga adunay giplano nga pagsusi.Nung nanung opsyon ing bagay depende king kayang ibie a ligtas ning unit mu, king access mu king uyat, at kareng layunin mu. Nung kaya ning center mu ing high-volume HDF, kutnan mu nung bagay ya keka. Nung e, malyari dang pisabyan ing HDx bilang pamalit filter para king metung a siguradung layunin, a atin planung pamanuri.

What stays the same, and when to speak upAno ang nananatiling pareho, at kailan dapat magsalitaUnsa ang magpabiling parehas, ug kanus-a mosultiNanu ing mananatiling pareu, at kapilan dapat magsalita

⛔

Tell the staff right away during treatment if you haveSabihin agad sa staff habang ginagamot kung mayroon kangIsulti dayon sa staff samtang gitambalan kung aduna kaySabyan me agad ing staff kabang gagamutan ka nung atin kang

Trouble breathing, chest pain or tightness, feeling faint or dizzy, itching with hives, swelling of the lips or face, back pain, or any new or strange feeling after the treatment starts. These can happen with any dialysis filter and need checking at once. At home, go to the emergency room for breathing trouble or chest pain.Hirap huminga, pananakit o paninikip ng dibdib, pakiramdam na mahihimatay o nahihilo, pangangati na may pantal, pamamaga ng labi o mukha, pananakit ng likod, o anumang bago o kakaibang pakiramdam pagkatapos magsimula ang gamutan. Maaari itong mangyari sa anumang dialysis filter at kailangang suriin agad. Sa bahay, pumunta sa emergency room kung hirap huminga o sumasakit ang dibdib.Kalisod sa pagginhawa, sakit o pagkahugot sa dughan, pamati nga maluya o malipong, katol nga adunay pantal, paghubag sa ngabil o nawong, sakit sa likod, o bisan unsang bag-o o katingad-an nga pamati human magsugod ang pagtambal. Mahimo kini mahitabo sa bisan unsang dialysis filter ug kinahanglan susihon dayon. Sa balay, adto sa emergency room kung lisod moginhawa o masakit ang dughan.Mirap manyawa, sakit o paninikip ning salu (chest tightness), pamakiramdam a mamatwa o mangalimu, kati a atin pantal, pamaga ning labi o lupa, sakit ning gulut, o nanumang bayu o kakaibang pamakiramdam kaibat mumpisa ing panulu. Malyari yang maliari king nanumang dialysis filter at kailangan yang surian agad. King bale, munta ka king emergency room nung mirap manyawa o masakit ing salu.

Will the new filter change what I pay?Magbabago ba ang babayaran ko dahil sa bagong filter?Mausab ba ang akong bayronon tungod sa bag-ong filter?Mibayu ya ing bayaran ku uli ning bayung filter?

HDx filters usually cost the dialysis unit more than regular filters. How that cost is handled differs between centers. PhilHealth (the Philippine Health Insurance Corporation) covers up to 156 hemodialysis sessions a year, enough for three a week, but its published benefit does not tell you whether a particular filter brand adds a charge at your unit. Ask your center directly, before the switch, whether HDx changes your out-of-pocket amount, and ask for the answer in writing if it does.Kadalasang mas mahal para sa dialysis unit ang filter ng HDx kaysa sa karaniwang filter. Iba-iba sa bawat center kung paano ito binabayaran. Sakop ng PhilHealth (Philippine Health Insurance Corporation) ang hanggang 156 na hemodialysis session kada taon, sapat para sa tatlo kada linggo, pero hindi sinasabi ng nailathalang benepisyo kung may dagdag na singil ang isang partikular na filter sa iyong unit. Direktang itanong sa iyong center, bago lumipat, kung binabago ng HDx ang iyong out-of-pocket na babayaran, at hingin ang sagot nang nakasulat kung oo.Kasagaran mas mahal alang sa dialysis unit ang filter sa HDx kaysa sa naandang filter. Lahi-lahi sa matag center kung giunsa kini pagbayad. Sakop sa PhilHealth (Philippine Health Insurance Corporation) ang hangtod 156 ka hemodialysis session matag tuig, igo alang sa tulo matag semana, apan wala gisulti sa gipatik nga benepisyo kung adunay dugang bayad ang usa ka partikular nga filter sa imong unit. Pangutan-a direkta ang imong center, sa dili pa mobalhin, kung mausab ba sa HDx ang imong out-of-pocket nga bayronon, ug pangayoa ang tubag nga nakasulat kung oo.Karaniwan yang mas mal para king dialysis unit ing filter ning HDx nung ing karaniwang filter. Mikakaiba king balang center nung makananu ya bayaran. Sakup ning PhilHealth (Philippine Health Insurance Corporation) anggang 156 a hemodialysis session king metung a banwa, sapat para king atlu king dominggu, pero e na sasabyan ning pepalwal a benepisyu nung atin dagdag a singil ing metung a partikular a filter king unit mu. Kutnan mu direkta ing center mu, bayu ka lumipat, nung bayuan na ning HDx ing out-of-pocket a bayaran mu, at buri me ing sagot a makasulat nung wa.

Six questions to bring to your nephrologistAnim na tanong na dadalhin sa iyong nephrologistUnom ka pangutana nga dad-on sa imong nephrologistAnam a kutang a darwan mu king nephrologist mu

  1. Which filter are we considering, and why for me?Aling filter ang pinag-iisipan natin, at bakit para sa akin?Unsang filter ang atong gikonsiderar, ug ngano alang kanako?Nanung filter ing isipan tamu, at nanu ya para kanaku?
  2. What problem are we trying to solve — itching, tiredness, recovery time, something else?Anong problema ang sinusubukan nating lutasin — kati, pagod, tagal ng paggaling, o iba pa?Unsang problema ang atong gisulayan sulbaron — katol, kakapoy, gitas-on sa pagkaayo, o uban pa?Nanung problema ing pakisanmetung tamung lutasan — kati, kapagal, kabayan ning pamanyawa, o aliwa pa?
  3. What else might explain my symptoms, and have we checked those first?Ano pa ang maaaring magpaliwanag sa aking mga sintomas, at nasuri na ba natin ang mga iyon?Unsa pa ang mahimong makapasabot sa akong mga sintomas, ug nasusi na ba nato kadto?Nanu pa ing malyaring magpaliwanag kareng sintomas ku, at asuri tana reta?
  4. How and when will we review whether it is helping me?Paano at kailan natin susuriin kung nakakatulong ito sa akin?Unsaon ug kanus-a nato susihon kung makatabang ba kini kanako?Makananu at kapilan tamu surian nung tutulung ya kanaku?
  5. Is online HDF an option at this center?Mayroon bang online HDF sa center na ito?Aduna bay online HDF sa kini nga center?Atin yang online HDF king center a iti?
  6. Will this change what I pay?Magbabago ba ang babayaran ko?Mausab ba ang akong bayronon?Mibayu ya ing bayaran ku?

Common questionsMga karaniwang tanongMga kasagarang pangutanaReng karaniwang kutang

Will HDx let me have fewer or shorter sessions?Mapapaikli ba o mababawasan ang aking session dahil sa HDx?Mamubo ba o makunhuran ang akong session tungod sa HDx?Mapaikli ya o mabawasan ing session ku uli ning HDx?
No. Session time and frequency depend on your small-waste clearance, fluid, potassium, your remaining kidney function, and how you feel. The filter does not replace those checks.Hindi. Nakadepende ang oras at dalas ng session sa pag-alis ng maliliit na dumi, tubig, potassium, natitirang gana ng bato, at pakiramdam mo. Hindi pinapalitan ng filter ang mga pagsusuring iyon.Dili. Nagdepende ang oras ug kadaghan sa session sa pagtangtang sa gagmay nga hugaw, tubig, potassium, nabilin nga gana sa bato, ug imong pamati. Dili ilisan sa filter kadtong mga pagsusi.E. Makadepende ing oras at dalas ning session king pamamako kareng malating dinat, danum, potassium, kakatagal a gana ning batu, at pamakiramdam mu. E na pamalitan ning filter deng pamanuring reta.
If I feel no different, should I stay on it?Kung wala akong nararamdamang pagbabago, dapat ko bang ituloy?Kung wala koy mabatyang kausaban, angay ba nako kining ipadayon?Nung ala kung damdaman a pamagbayu, dapat ke ya ituloy?
That is a fair question to bring to your review. If the goal you named has not improved, it is reasonable to discuss returning to your previous filter, especially if HDx costs you more.Makatwirang tanong ito sa iyong pagsusuri. Kung hindi bumuti ang layuning pinangalanan mo, makatwirang pag-usapan ang pagbalik sa dating filter, lalo na kung mas mahal ang HDx para sa iyo.Makataronganon kini nga pangutana sa imong pagsusi. Kung wala mouswag ang tumong nga imong ginganlan, makataronganon nga hisgotan ang pagbalik sa kanhing filter, labi na kung mas mahal ang HDx kanimo.Makatuwirang kutang ya iti king pamanuri mu. Nung e ya mipayap ing layunin a linagyu mu, makatuwiran yang pisabyan ing pamibalik king dating filter, lalu na nung mas mal ya keka ing HDx.
Is HDx the same as hemodiafiltration?Pareho ba ang HDx at hemodiafiltration?Parehas ba ang HDx ug hemodiafiltration?Pareu ya ing HDx at hemodiafiltration?
No. HDx changes only the filter on a regular machine. Hemodiafiltration needs a special machine that adds and removes large volumes of clean fluid. The two have different evidence, as the table above shows.Hindi. Filter lang ang binabago ng HDx sa karaniwang makina. Kailangan ng hemodiafiltration ang espesyal na makina na nagdadagdag at nag-aalis ng maraming malinis na likido. Magkaiba ang ebidensya ng dalawa, gaya ng nasa talahanayan sa itaas.Dili. Filter ra ang usbon sa HDx sa naandang makina. Kinahanglan sa hemodiafiltration ang espesyal nga makina nga modugang ug motangtang og daghang limpyo nga likido. Lahi ang ebidensya sa duha, sama sa naa sa talaan sa ibabaw.E. Filter mu ing bayuan ning HDx king karaniwang makina. Kailangan ning hemodiafiltration ing espesyal a makina a magdagdag at mamako dakal a malinis a likidu. Mikakaiba ing ebidensya ning adwa, anti ning atyu king talaan king babo.

Expanded hemodialysis: what it is, what it is not, and where the evidence stands

Expanded hemodialysis (HDx) is conventional diffusive hemodialysis (HD) delivered through a medium cut-off (MCO) membrane engineered for greater permeability to large middle molecules (roughly 15–45 kDa) with limited albumin passage. With a studied MCO dialyzer, HDx reliably removes more of these solutes per session than high-flux HD. Whether that translates into longer survival remains unknown. Japanese super high-flux (SHF) dialyzers are a related but heterogeneous group with their own classification and registry literature. High-volume online hemodiafiltration (HDF) is a separate modality with randomized survival evidence in eligible patients. This guide keeps these three evidence lanes apart throughout, because conflating them is the commonest error in HDx discussions.

Why the question matters. Survival on maintenance HD remains poor, and the residual excess risk is not explained by small-solute dose: the HEMO-era lesson was that pushing urea clearance beyond the KDOQI (Kidney Disease Outcomes Quality Initiative) target adds little. Attention therefore turned to solutes that urea kinetics ignore. Middle molecules such as β2-microglobulin (β2M), free light chains (FLC), complement factor D, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) accumulate in kidney failure and are associated with inflammation, cardiovascular disease, amyloidosis and symptom burden. Removing them is mechanistically plausible as a target. Whether they are causal mediators that dialytic removal can modify is a hypothesis, and that is exactly where HDx and HDF evidence diverge.

Three-lane comparison card: lane one, MCO expanded hemodialysis on a standard machine, with greater lambda free light chain removal (33% vs 17% in a randomized trial), a small early albumin dip, strong removal evidence and unproven survival; lane two, Japanese super high-flux dialyzers classified by beta-2 microglobulin clearance of 70 mL/min or more and albumin sieving, with registry associations; lane three, high-volume online hemodiafiltration with an ultrapure fluid module, 23 L or more of convection per session and an all-cause death hazard ratio of 0.77 in CONVINCE, with randomized survival evidence.

Three lanes, three evidence bases. MCO HDx: strong solute evidence, uncertain survival. Japanese SHF: registry associations under Japanese conditions. High-volume online HDF: randomized survival benefit at ≥ 23 L convection.

HDx
Expanded hemodialysis
MCO
Medium cut-off
SHF
Super high-flux
HDF
Hemodiafiltration
RCT
Randomized controlled trial
🔬

Three practices that are often blurred

(1) MCO HDx: a membrane change on a standard HD machine, studied mainly with Theranova 400/500 (Baxter); cite model-specific data. (2) Japanese SHF dialyzers: classified by β2M clearance and albumin sieving coefficient under Japanese test conditions; their registry associations do not transfer automatically to MCO trials or vice versa. (3) High-volume online HDF: post-dilution convection ≥ 23 L/session with ultrapure substitution fluid; its mortality evidence belongs to that delivery strategy only. A fourth, protein-leaking and high cut-off (HCO) dialyzers, has distinct indications (for example, myeloma cast nephropathy studies) and is not routine maintenance HDx.

Diffusion, convection, and membrane selectivity

Normal physiology first. The glomerular barrier sieves by size, shape and charge: small solutes pass freely, β2M (about 11.8 kDa) is filtered and then reabsorbed and catabolized by the proximal tubule, and albumin (about 66.5 kDa) is almost entirely retained. Native kidneys therefore clear large middle molecules continuously, all week. Intermittent dialysis must approximate that in roughly 12 hours, through a synthetic barrier whose selectivity is far blunter than the glomerulus.

Two transport mechanisms. Diffusion moves solute down a concentration gradient; its rate falls steeply with molecular size, which is why high-flux HD clears urea (60 Da) superbly and λ-FLC (about 45 kDa as a dimer) poorly. Convection drags solute with water flow (solvent drag); its efficiency depends on the membrane's sieving coefficient for that solute rather than on diffusivity, so it favors larger molecules. Online HDF adds convection externally, by ultrafiltering large volumes and reinfusing substitution fluid. MCO HDx adds it internally.

Internal filtration and backfiltration. Along a hollow fiber, blood-side pressure falls from inlet to outlet while dialysate-side pressure runs in the opposite direction. Near the blood inlet, water filters out of the blood (internal filtration); near the outlet, dialysate flows back in (backfiltration). Net fluid removal from the patient is unchanged, but a substantial internal convective exchange occurs. MCO fibers have a smaller inner diameter, which raises axial pressure drop and internal filtration, and a tighter pore-size distribution, which raises sieving of large middle molecules while keeping albumin sieving low. Because this convection is not externally measured or prescribed, it cannot be audited like an HDF convection volume (Bergling & Blankestijn, 2026). Backfiltration also makes dialysate purity a patient-safety issue, as with any high-permeability membrane.

Review-article mechanism schematic: a dialyzer cartridge at left, a dashed magnified panel of one hollow fiber showing blood flowing left to right and dialysate counter-current, internal filtration arrows leaving the fiber near the blood inlet and backfiltration arrows entering near the outlet, with medium molecules crossing the wall and albumin retained; a bottom flow strip reads larger pores and narrower fiber, more internal convection, more large-middle-molecule removal, albumin and dialysate purity monitored.

Inside one MCO fiber: filtration out near the blood inlet, backfiltration in near the outlet. The internal exchange adds convection without changing net fluid removal, so large middle molecules leave while most albumin stays.

MCO
Medium cut-off
Qb
Blood flow rate
Qd
Dialysate flow rate
TMP
Transmembrane pressure
β₂M
β2-microglobulin

Keep four membrane properties separate

FluxThe ultrafiltration (UF) coefficient, KUF (mL/h/mmHg), measures hydraulic permeability and defines "flux". It says nothing on its own about which solutes cross (Bowry et al., 2021).
ClearanceSolute removal rate at stated Qb, Qd and surface area; device- and condition-specific.
SievingThe sieving coefficient (SC) is the filtrate-to-plasma concentration ratio for a solute in pure convection. Molecular weight retention onset (MWRO) is the mass at SC 0.9; molecular weight cut-off (MWCO) is the mass at SC 0.1. Both are bench descriptors under specified test conditions.
Albumin lossMeasured dialysate albumin mass (g/session). Depends on membrane, transmembrane pressure (TMP), time, and secondary protein layer; not derivable from catalog SC alone.
Bench curves and in-session reduction ratios answer different questions. A reduction ratio describes a concentration change over one session; it is not clearance, not mass removed, and not an adequacy target.
Qualitative schematic of sieving coefficient versus molecular mass with illustrative spacing: a low-flux curve falling early, a high-flux curve falling before 20 kDa, an MCO curve staying high through roughly 30 to 45 kDa and dropping steeply before albumin, and a high cut-off curve passing albumin; landmark markers for urea, beta-2 microglobulin, lambda free light chain dimer and albumin, with no numeric y-axis values.

Qualitative sieving profiles, not bench data. The MCO goal is a steep drop between λ-FLC (about 45 kDa) and albumin (about 66 kDa). High cut-off membranes pass albumin and belong to other indications.

SC
Sieving coefficient
MWRO
Molecular weight retention onset (SC 0.9)
MWCO
Molecular weight cut-off (SC 0.1)
λ-FLC
Lambda free light chain
HCO
High cut-off
kDa
Kilodalton

Membrane taxonomy

TermHow to use it
Conventional high-flux HDMain comparator. Excellent small-solute clearance, partial β2M removal, poor removal above about 25 kDa. The specific comparator membrane and delivered treatment matter when reading trials.
MCO HDxConventional HD mode with an MCO membrane. Cite model-specific data (Theranova 400 = 1.7 m², 500 = 2.0 m²). The US Food and Drug Administration (FDA) De Novo decision (DEN190042) indicates them for intermittent HD in chronic kidney failure and not for HDF or hemofiltration.
Japanese SHFLegacy Types IV (β2M clearance 50 to < 70 mL/min) and V (≥ 70 mL/min). Current Japanese classification: Type I (< 70) vs Type II (≥ 70 mL/min), each split by albumin SC < 0.03 (a) or ≥ 0.03 (b), plus Type S (adsorptive or biocompatibility-enhanced). Preserve classification year and test conditions (Abe, 2026).
Protein-leaking and HCOAlbumin permeability is a deliberate, device-specific trade-off. Keep HCO evidence (including myeloma cast nephropathy) separate from routine maintenance HDx.
High-volume online HDFSeparate modality: compatible machine, online ultrapure substitution fluid, stated dilution mode (pre-, post-, mixed) and delivered convection volume.

Molecular landmarks and why one session tells only part of the story

SoluteApprox. massInterpretive caveat
Urea60 DaBasis of Kt/V; freely diffusible; rebound modest.
β2M~11.8 kDaGeneration is fairly constant; slow intercompartmental transfer causes post-dialysis rebound; residual kidney function contributes substantially to clearance.
κ-FLC (monomer) / λ-FLC (dimer)~22.5 / ~45 kDaλ-FLC reduction ratio is the usual MCO efficacy endpoint; polyclonal levels rise with inflammation and falling residual function.
Albumin~66.5 kDaSafety endpoint. Serum concentration reflects synthesis, inflammation, dilution, intake and losses, not dialyzer loss alone.
Indoxyl sulfate, p-cresyl sulfateSmall, protein-boundRemoval limited by albumin binding, not pore size. A 2026 randomized study found no difference between MCO HD and online HDF over 4 weeks (Herič et al., 2026). Do not group these with free middle molecules.

The evidence, lane by lane

Each row names the design, population, comparator, endpoint class and horizon. Endpoint classes are labeled Session clearance Serum or residual function Clinical event and patient-reported outcomes (PROs). Randomized controlled trial (RCT) designs are named in each row; certainty labels are the study's own where reported; interpretation is editorial.

Lane 1 — MCO HDx versus high-flux HD

StudyDesign and populationKey resultInterpretation and limits
Weiner et al., 2020RCT, 172 prevalent HD adults (US), Theranova 400 vs Elisio-17H, 24 weeksSession λ-FLC reduction ratio 33% vs 17% at week 24 (P < 0.001); larger reductions for β2M, complement factor D, TNF-α, not IL-6. Predialysis albumin 4.0 vs 4.1 g/dL, meeting non-inferiority.Clear removal advantage in this comparison. Albumin concentration was the safety endpoint, not albumin mass. Industry-funded; 65/86 completed per arm; not powered for clinical outcomes.
Kandi et al., 2022a (biomarkers)Systematic review, 26 studies (10 randomized), 1,883 patientsSession Dialysate albumin removal +2.31 g/session (95% confidence interval [CI] 1.83 to 2.79). Serum Predialysis albumin −0.12 g/dL in the first 24 weeks (95% CI −0.16 to −0.07), returning to baseline thereafter (−0.02 g/dL). Large increases in β2M, κ/λ-FLC and myoglobin removal (high certainty).The 2.31 g is a between-group mean difference; the published abstract prints its interval reversed (2.79 to 1.83). The early albumin dip is small, transient and consistent across studies. High certainty applies to the measured biomarker, not to clinical benefit.
Kandi et al., 2022b (clinical outcomes)Systematic review, 22 studies (6 randomized, 16 nonrandomized), 1,811 patientsPRO Pruritus −4.4 points (95% CI −7.1 to −1.7; 1 RCT, n = 49; moderate). Event Hospitalization rate ratio 0.48 (0.27–0.84; 1 RCT; low). Mortality risk difference −0.4% (−2.8 to 2.1).Two RCTs showed little or no overall quality-of-life (QoL) difference (low certainty). The headline "+16.7/100 QoL" came from one 28-patient nonrandomized subgroup with low baseline scores; the 420-minute recovery-time reduction came from one nonrandomized study. Most mortality arms had zero events.
Mok et al., 2025RCT, 60 prevalent HD adults (Hong Kong), 60% twice weekly, 12 monthsSerum MCO albumin 3.79 → 3.62 g/dL at 6 months vs control 3.84, then back to baseline. No difference in body composition, PROs or clinical events at 12 months.Small exploratory trial, but the setting (lower dialysis dose, twice-weekly schedules) resembles many Philippine units. Suggests the added removal may add little benefit when the delivered dose is low.
Lim et al., 2025 (Theranova versus High-flux Dialyzer on Preservation of Residual Renal Function, THREAD)RCT, 80 incident HD adults (Korea), Theranova 400 vs FX CorDiax 80, 12 monthsResidual function Glomerular filtration rate (GFR) change −1.0 vs −2.4 mL/min/1.73 m²; difference −1.4 (95% CI −2.4 to −0.5). Urine volume advantage through month 9, not at 12.Promising single-trial signal on a patient-relevant surrogate. Open-label; GFR as mean of urea and creatinine clearance; underpowered for hospitalization or death.
Penny et al., 2025Interventional on–off–on design, 47 thrice-weekly patients (Canada), 15 monthsPRO Health-related quality of life (HRQoL) +19% from baseline; pruritus −30%, energy +33%, recovery +26%, with improvement fading on return to high-flux and recurring on reintroduction.Withdrawal–reintroduction strengthens causal inference, but the study was unblinded and small. Larger responses in those with worse baseline burden.
Castillo et al., 2025Retrospective cohort, 1,092 prevalent HD adults (Colombia), up to 4 yearsEvent Fine–Gray subdistribution hazard ratio (HR) for death from causes other than coronavirus disease 2019 (COVID-19) 0.79 (95% CI 0.62–0.98), COVID-19 death as competing risk.Association only; residual confounding and treatment selection possible; manufacturer-linked authors. Quote the endpoint and model with the number.

Lane 2 — Japanese super high-flux registry data

StudyDesign and populationKey resultInterpretation and limits
Abe et al., 2024Japanese Society for Dialysis Therapy (JSDT) registry, 181,804 HD patients, 2-year follow-upEvent Adjusted all-cause mortality HR vs Type Ia: 0.91 (reported 95% CI 0.87–0.93) for Type IIa and 0.87 (0.78–0.97) for IIb, in the model including nutrition and inflammation covariates; consistent after propensity matching.Association under Japanese practice (long sessions, low mortality, distinct case mix). Results vary with covariates and cohort definition. Keep separate from Theranova trials and older Type IV/V cohorts.

Lane 3 — HDx versus online HDF, and HDF versus HD

StudyDesign and populationKey resultInterpretation and limits
Gan et al., 2025RCT, 274 prevalent HD patients (China), single mid-week session, HDx vs post-dilution online HDFSession λ-FLC reduction ratio +17.0% with HDx (95% CI 14.8 to 19.2, superior); β2M −1.2% (−2.5 to 0.2, non-inferior). No differences in Kt/V or complications.Removal parity or better for large middle molecules in one session. Says nothing about outcomes; convection volume in the HDF arm determines the comparison.
Lee et al., 2021 (Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration, CARTOON)RCT, 80 randomized (65 completed), thrice-weekly HDx vs online HDF, 1 yearSurrogate No difference in pulse wave velocity or echocardiography. Coronary calcium rose with HDx vs stable on HDF (P = 0.012).Small, open-label surrogate study with missing calcium data. Does not establish equivalence or justify routine calcium scanning.
Aktas et al., 2025Meta-analysis, 8 studies, 614 patients, HDx vs online HDFEvent All-cause mortality risk ratio (RR) 0.97 (95% CI 0.62–1.53).The interval is compatible with substantial benefit or harm; absence of difference is not equivalence.
Blankestijn et al., 2023 (CONVINCE)RCT, 1,360 adults able to reach ≥ 23 L/session, high-dose online HDF vs high-flux HD, median 30 monthsEvent All-cause death 17.3% vs 21.9%; HR 0.77 (95% CI 0.65–0.93). Mean convection 25.3 L/session.About 4.6 percentage points absolute difference over 30 months (number needed to treat ≈ 22). Applies to the studied delivery strategy and selected population.
Vernooij et al., 2024Individual participant data (IPD) meta-analysis, 5 RCTs, 4,153 patientsEvent All-cause mortality HR 0.84 (0.74–0.95); cardiovascular HR 0.78 (0.64–0.96); graded benefit with convection volume.Dose–response is observational within trials; includes CONVINCE.
Vernooij et al., 2026 (Cochrane)62 RCTs (6,897 participants), search to April 2025Event Convective vs diffusive: death RR 0.88 (0.80–0.96), cardiovascular death RR 0.78 (0.66–0.92), moderate certainty.Only 4 studies (163 participants) addressed HDx; the convective estimate cannot be assigned to HDx.
⚠️

Read the numbers by metric

Hazard ratios, subdistribution hazard ratios, rate ratios, mean differences in g/dL and percentage-point differences in reduction ratio are different quantities; they cannot be compared across rows. The HDF mortality benefit is not evidence for HDx, and a CI that crosses 1 in a small HDx-versus-HDF meta-analysis is not evidence that the two are equivalent.

Recommendations and a selective HDx pilot

1. Keep routine HD care in place first. Optimize delivered time and small-solute dose, access function, volume and ultrafiltration rate, treatment tolerance, nutrition and symptom evaluation. KDOQI 2015 targets a single-pool Kt/V (spKt/V) of 1.4 per thrice-weekly session with a minimum delivered 1.2; for other schedules, a weekly standard Kt/V of 2.3 with a minimum of 2.1, including ultrafiltration and residual kidney function contributions. A new membrane does not compensate for missed time or a failing access.

2. Discuss high-volume online HDF where it is deliverable and appropriate. It is the only enhanced-clearance modality with randomized survival evidence. Check access and achievable blood flow, staff capability, compatible machines, water and fluid quality, and patient preference. The 2025 EuDial (European Dialysis) Working Group consensus of the European Renal Association (ERA) and the 2026 Italian Society of Nephrology guidance concern HDF (the Italian panel recommends post-dilution HDF to reduce cardiovascular mortality and suggests high-volume HDF to reduce all-cause mortality, moderate certainty); neither addresses HDx directly.

3. Consider HDx selectively, as a defined trial, where HDF is unavailable or unsuitable. The following is a proposed local workflow, not a guideline. It suits a stable adult on maintenance HD with a specific, measurable goal (most often pruritus, post-dialysis recovery time or fatigue) after remediable causes have been addressed, with shared decision-making about uncertain benefit and any cost. Defer an elective switch while an unexplained falling albumin, active illness or significant nutritional decline is being evaluated.

Selective HDx pilot: from readiness to audit
1
Readiness (unit). Medical director and nursing confirm Philippine FDA registration and the local instructions for use (IFU) for the exact model, machine and ultrafiltration (UF) control compatibility, priming, extracorporeal volume, reaction procedures and fallback stock. Biomedical staff confirm water and dialysate quality, sampling and excursion response. Pharmacy reviews dialyzable drugs and timing; the FDA review flagged possible removal of some medications and essential proteins.
2
Baseline (patient). Record model, access, delivered time, Qb/Qd, net UF and UF rate, blood pressure tolerance, missed time and urea adequacy. Draw comparable predialysis albumin (same weekday, same assay) and note recent illness, fluid status, appetite and weight trend. Document one goal with a repeatable measure (for example a 0–10 itch score or minutes to recover). Measure residual function when it informs interpretation.
3
Switch and monitor. Follow device IFU. Track lot, reactions, clotting and interruptions. Proposed cadence: baseline, 2–4 weeks, then monthly to a 12-week review, individualized. Repeat an unexpected albumin result and evaluate volume, infection, intake and protein losses before attributing it to the membrane.
4
Review and decide at about 12 weeks. Continue if the goal improved meaningfully for that patient and safety is satisfactory; return to the prior membrane if not, or if cost burden outweighs benefit. Escalate any sustained unexplained albumin fall, nutritional decline, worse tolerance or falling delivered adequacy.
5
Audit. Use defined denominators: eligible, offered, switched, completed review, albumin pairs available, goal measured, discontinuations and reasons. Report reactions per 100 delivered sessions. Keep before–after descriptions separate from efficacy claims.
Clinical algorithm flowchart in journal style: start with a stable maintenance hemodialysis patient, optimize routine care, decide whether high-volume online hemodiafiltration is deliverable, then for an HDx trial define one measurable goal, record baseline, switch and monitor albumin and tolerance, and review at about 12 weeks with continue or revert branches and a red escalation box.

Decision path: optimize standard HD, consider high-volume HDF where deliverable, and use HDx as a goal-defined, time-limited trial with a planned review and clear stopping rules.

HD
Hemodialysis
HDF
Hemodiafiltration
HDx
Expanded hemodialysis
IFU
Instructions for use
UF
Ultrafiltration

Copy-ready trial note

Paste into the chart at the start of a pilot; fill the brackets.

HDx TRIAL — start [date]
Dialyzer: [model, m²]   Prior: [model]   Schedule: [x/week, h]
Goal (patient-named): [e.g., night itch]   Measure: [0–10 score / minutes to recover]
Baseline: score [ ]  Alb [ ] g/dL ([assay], [weekday])  spKt/V [ ]  Qb/Qd [ ]  UF rate [ ]
Remediable causes reviewed: [xerosis / meds / parathyroid–phosphate / adequacy / other]
Monitoring: Alb + goal at 2–4 wk, then monthly; reactions/clotting each session
Review: [date ≈ 12 wk] — continue if goal improved and safe; revert otherwise
Cost discussed: [yes/no; amount]   Pharmacy review: [done]

Interpreting albumin after a switch

Serum albumin is a poor single marker of dialyzer loss. It is diluted by volume expansion, suppressed as a negative acute-phase reactant by inflammation, lowered by inadequate protein-energy intake, and affected by urinary or gastrointestinal losses and by assay method (bromocresol green reads higher than bromocresol purple). The KDOQI 2020 nutrition guideline places albumin within a broader assessment of intake, body composition and inflammation (Ikizler et al., 2020). Against that background, the expected MCO effect is small: about −0.1 g/dL in the first months, recovering by six months on pooled data. A larger or persistent fall therefore deserves a search for another cause before the membrane is blamed — and, if no cause is found, a return to the prior membrane.

Minimal organ-sigil diagram with a central serum albumin drop connected by dotted arrows to a liver icon for synthesis, a flame icon for inflammation, a bowl icon for dietary protein, a water droplet for dilution from fluid excess, a kidney icon for urinary loss, and a dialyzer icon for membrane loss, with the dialyzer arrow drawn thinnest.

Serum albumin sits at the meeting point of synthesis, inflammation, intake, dilution and losses. Dialyzer loss is usually the smallest contributor, so look at the whole picture before blaming the membrane.

CRP
C-reactive protein
MCO
Medium cut-off

Devices, payment, and practice in the Philippines

Device registration. Verify the exact model's Philippine FDA registration, local IFU and supplier documents before procurement; foreign labeling (for example FDA DEN190042 in the US) does not establish local status. Payment. PhilHealth covers up to 156 hemodialysis sessions a year (2025 expansion), but published benefit materials do not differentiate dialyzer types; confirm with the facility how any price difference is absorbed or passed to patients, and model budgets with actual contracted prices. A 2026 Colombian budget-impact model reported savings driven by fewer hospitalizations (Sanabria et al., 2026), but its effect inputs came from observational data from the same network, so those savings should not be imported into local models.

Practice pattern. Twice-weekly schedules and modest blood flows are common in Philippine units. Mok et al. (2025) — the trial closest to that setting — found no clinical advantage for MCO over 12 months at a lower dialysis dose, and internal convection depends on blood flow and fiber pressure drop (an inference from mechanism, not a measured local finding). The priority for most patients remains delivered time, frequency matched to measured residual function, access and volume control. Water. Backfiltration across high-permeability membranes makes dialysate purity central; International Organization for Standardization (ISO) 23500-3 (water) and 23500-5 (dialysis fluid) address these separately, and the unit's applicable standard and IFU set operational limits.

Four practical cases

1. Persistent itch despite adequate dialysis Symptom-directed trial

A 58-year-old on thrice-weekly HD (spKt/V 1.5) scores night itch 7/10. First review xerosis, medications, calcium–phosphate and parathyroid hormone control, and adequacy. If itch persists and HDx is chosen, record the baseline score and set a 12-week review. Agree in advance what counts as meaningful (for example a fall of ≥ 3 points with better sleep). The best randomized pruritus estimate is a −4.4-point difference from one 49-patient RCT; individual response varies.

2. Albumin falls during an infection Competing causes

Six weeks after a switch, albumin drops from 3.9 to 3.4 g/dL during a catheter-related bloodstream infection. Confirm same assay and weekday sampling, assess intake and volume, treat the infection, and repeat once the illness settles. If albumin recovers, the membrane was unlikely to be the main driver; if it stays low without another explanation, return to the prior dialyzer and involve the dietitian.

3. Twice-weekly start with urine output Residual function

A 49-year-old starting twice-weekly HD passes 900 mL/day. Measure residual urea clearance from a timed collection, check weekly standard Kt/V and volume, and plan re-measurement. THREAD is a residual-function signal in thrice-weekly incident patients; Mok provides context for twice-weekly treatment. Neither result decides this patient's frequency, which depends on measured residual function (see Incremental Dialysis).

4. A center weighing HDF against an HDx pilot Unit decision

A unit has standard machines and is pricing online HDF. Compare infrastructure (machines, ultrapure fluid, microbiological surveillance), achievable convection (access, blood flow, session time), staffing and procurement for HDF against an HDx pilot's dialyzer cost and monitoring burden. Present each option with its own evidence: randomized survival benefit for high-volume HDF; removal and symptom data, but no proven survival benefit, for HDx.

What is coming

StudyStatus and designWhy it matters
DIALEX (DIALysis with EXpanded solute removal; NCT06660277)Pragmatic open-label RCT in Canada, 4,800 participants (SHF Elisio HX vs high-flux), primary outcome all-cause mortality, mean follow-up 2.9 years; recruiting, primary completion estimated 2031Powered for a hazard ratio of 0.85; the first trial able to answer the survival question for an expanded-removal dialyzer.
REMOV-HDx (NCT07348536)Single-center crossover, 15 participants, HDx at 180/210/240 min vs high-volume HDF, global removal score; registered 2026Informs HDx session-length prescription; removal endpoint only.
Levin Iaina et al., 202540 patients, sequential quasi-random allocation, Theranova 500 vs Revaclear 500, 24 weeksspKt/V rose 1.24 → 1.40 within the HDx arm; global Kidney Disease Quality of Life (KDQOL) domains improved similarly in both arms. Within-arm change is not a between-arm effect.
Reque Santivañez et al., 2026Spanish home HDx cohort, 33 patients, design and baseline reportFirst structured data on HDx in frequent home HD; outcomes pending.

Registry status and dates were checked on 10 November 2026 and should be refreshed from ClinicalTrials.gov at each review.

How certain is each claim?

ClaimCertaintyMain sources
MCO HDx removes more large middle molecules per session than high-flux HDHigh (biomarker endpoint), replicated RCTsWeiner 2020; Kandi 2022a
MCO causes a small, transient fall in serum albuminHigh for the measured change (about −0.1 g/dL, first 24 weeks)Kandi 2022a; Mok 2025
HDx reduces pruritus or recovery timeModerate for pruritus (one RCT); recovery time from nonrandomized dataKandi 2022b; Penny 2025
HDx reduces hospitalizationLow (one RCT, wide CI)Kandi 2022b
HDx slows loss of residual kidney functionSingle RCT signalLim 2025 (THREAD)
HDx improves survivalUnproven; observational associations onlyCastillo 2025; DIALEX pending
SHF dialyzers (β2M clearance ≥ 70 mL/min) associated with lower mortality in JapanRegistry associationAbe 2024
High-volume online HDF reduces all-cause mortalityModerate-certainty randomized evidenceCONVINCE 2023; Vernooij 2024; Cochrane 2026
HDx and online HDF have equivalent outcomesNot establishedAktas 2025; CARTOON 2021
🔭

What may change

Evidence was checked on 10 November 2026 through targeted PubMed searches for expanded hemodialysis, medium cut-off and super high-flux terms. This page should be re-reviewed at six months, or sooner when DIALEX or another major HDx trial reports, when device labeling changes, or when a society issues HDx-specific guidance.

Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

β₂M
β2-microglobulin — a middle molecule of about 12 kDa used to compare dialyzers.β2-microglobulin — katamtamang laking molekula (mga 12 kDa) na ginagamit sa paghahambing ng dialyzer.β2-microglobulin — tunga-tunga nga molekula (mga 12 kDa) nga gigamit sa pagtandi sa dialyzer.β2-microglobulin — katamtamang molekula (mga 12 kDa) a gagamitan king pamanikuat da reng dialyzer.
CARTOON
Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration trial.
CI
Confidence interval — the range within which the true effect probably lies.
COVID-19
Coronavirus disease 2019.
CRP
C-reactive protein — a blood marker of inflammation.
DIALEX
DIALysis with EXpanded solute removal — a large Canadian trial testing whether expanded-removal dialyzers improve survival.DIALysis with EXpanded solute removal — malaking pag-aaral sa Canada kung nagpapahaba ng buhay ang mga filter na ito.DIALysis with EXpanded solute removal — dakong pagtuon sa Canada kung makapalugway ba sa kinabuhi kini nga mga filter.DIALysis with EXpanded solute removal — maragul a pag-aral king Canada nung pampaba ya bie deng filter a reti.
ERA
European Renal Association.
FDA
Food and Drug Administration (United States or Philippines, as stated).
FLC
Free light chains — antibody fragments (κ about 22.5 kDa; λ dimer about 45 kDa) used as markers of large middle-molecule removal.Free light chains — piraso ng antibody na ginagamit na palatandaan ng pag-alis ng malalaking katamtamang dumi.Free light chains — bahin sa antibody nga gigamit nga timailhan sa pagtangtang sa dagkong tunga-tunga nga hugaw.Free light chains — bage ning antibody a gagamitan bilang tanda ning pamamako kareng maragul a katamtamang dinat.
GFR
Glomerular filtration rate — how much blood the kidneys filter per minute.
HCO
High cut-off — dialyzers that deliberately let albumin pass; used for special indications.
HD
Hemodialysis — cleaning the blood through a filter outside the body.Hemodialysis — paglilinis ng dugo sa filter sa labas ng katawan.Hemodialysis — paglimpyo sa dugo pinaagi sa filter sa gawas sa lawas.Hemodialysis — pamaglinis ning daya king filter king luwal ning katawan.
HDF
Hemodiafiltration — hemodialysis plus large-volume fluid exchange with ultra-clean replacement fluid.Hemodiafiltration — hemodialysis kasama ang malaking palitan ng napakalinis na likido.Hemodiafiltration — hemodialysis uban ang dakong ilisan sa limpyo kaayo nga likido.Hemodiafiltration — hemodialysis kayabe ing maragul a pamalit ning malinis kaya a likidu.
HDx
Expanded hemodialysis — hemodialysis using a medium cut-off dialyzer.Expanded hemodialysis — hemodialysis gamit ang medium cut-off na dialyzer.Expanded hemodialysis — hemodialysis gamit ang medium cut-off nga dialyzer.Expanded hemodialysis — hemodialysis gamit ing medium cut-off a dialyzer.
HR
Hazard ratio — the relative rate of an event over time between two groups.
HRQoL
Health-related quality of life.
IFU
Instructions for use — the manufacturer's official device labeling.
IL-6
Interleukin-6 — an inflammatory signaling protein.
IPD
Individual participant data — a meta-analysis using each trial participant's records.
ISO
International Organization for Standardization.
JSDT
Japanese Society for Dialysis Therapy.
KDOQI
Kidney Disease Outcomes Quality Initiative (National Kidney Foundation guidelines).
KDQOL
Kidney Disease Quality of Life questionnaire.
KUF
Ultrafiltration coefficient — the hydraulic permeability that defines membrane "flux".
MCO
Medium cut-off — a dialyzer membrane designed to pass large middle molecules while holding back most albumin.Medium cut-off — filter na nagpapalabas ng malalaking katamtamang dumi habang pinipigilan ang karamihan ng albumin.Medium cut-off — filter nga mopagawas sa dagkong tunga-tunga nga hugaw samtang pugngan ang kadaghanan sa albumin.Medium cut-off — filter a paluwalan ing maragul a katamtamang dinat kabang pigilan ing kayaliwan ning albumin.
MWCO
Molecular weight cut-off — the mass at which the sieving coefficient falls to 0.1.
MWRO
Molecular weight retention onset — the mass at which the sieving coefficient falls to 0.9.
nPCR
Normalized protein catabolic rate — an estimate of daily protein intake in dialysis.
PD
Peritoneal dialysis.
PRO
Patient-reported outcome — a result reported directly by the patient, such as itch or fatigue scores.
Qb / Qd
Blood flow rate / dialysate flow rate (mL/min).
QoL
Quality of life.
RCT
Randomized controlled trial.
RR
Risk ratio or rate ratio, as stated.
SC
Sieving coefficient — filtrate-to-plasma concentration ratio of a solute during pure convection.
SHF
Super high-flux — Japanese dialyzer class with β2-microglobulin clearance of 70 mL/min or more under standard test conditions.
spKt/V
Single-pool Kt/V — per-session urea clearance relative to body water.
THREAD
Theranova versus High-flux Dialyzer on Preservation of Residual Renal Function trial.
TMP
Transmembrane pressure — the pressure difference driving fluid across the membrane.
TNF-α
Tumor necrosis factor-α — an inflammatory cytokine.
UF
Ultrafiltration — fluid removal during dialysis.

Terms

Albumin
The main blood protein, made by the liver; it holds water in the blood vessels and carries medicines.Pangunahing protina sa dugo na gawa ng atay; pinapanatili nito ang tubig sa mga ugat at nagdadala ng gamot.Panguna nga protina sa dugo nga gihimo sa atay; gipabilin niini ang tubig sa mga ugat ug nagdala og tambal.Pangunang protina king daya a gawa ning ati; panatilian na ing danum kareng uyat at mangawit gamut.
Backfiltration
Dialysate flowing back into the blood near the fiber outlet; balances internal filtration.
Convection
Solute carried along with water flow across a membrane; favors larger molecules.
Dalton
Unit of molecular mass; 1 kDa = 1,000 daltons.Yunit ng bigat ng molekula; 1 kDa = 1,000 dalton.Yunit sa bug-at sa molekula; 1 kDa = 1,000 ka dalton.Yunit ning bigat ning molekula; 1 kDa = 1,000 dalton.
Dialyzer
The dialysis filter: a cartridge of thousands of hollow fibers.Ang dialysis filter: kartutso ng libu-libong hollow fiber.Ang dialysis filter: kartutso sa linibo ka hollow fiber.Ing dialysis filter: kartutsu a atin libu-libung hollow fiber.
Diffusion
Solute movement down a concentration gradient; efficient for small molecules.
Internal filtration
Water and solute leaving the blood near the fiber inlet because of the pressure drop along the fiber.
Middle molecules
Uremic solutes of roughly 0.5–60 kDa, such as β2-microglobulin and free light chains, poorly removed by standard dialysis.Mga duming may katamtamang laki na mahirap alisin sa karaniwang dialysis.Mga hugaw nga tunga-tunga ang gidak-on nga lisod tangtangon sa naandang dialysis.Reng dinat a katamtaman ing kalagwan a mirap ilako king karaniwang dialysis.
Pruritus
Itching; common and distressing in kidney failure.Pangangati; karaniwan at nakababahala sa kidney failure.Katol; komon ug makahasol sa kidney failure.Kati; karaniwan at makaligalig king kidney failure.
Reduction ratio
The percentage fall in a solute's blood level over one session.
Residual kidney function
The kidney work that remains after dialysis starts.Natitirang gana ng bato pagkatapos magsimula ng dialysis.Nabilin nga gana sa bato human magsugod ang dialysis.Kakatagal a gana ning batu kaibat mumpisa ing dialysis.
ReferencesMga SanggunianMga TinubdanReng Reperensya 31 sources
  1. National Kidney Foundation (NKF). (2015). KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. American Journal of Kidney Diseases, 66(5), 884–930. https://doi.org/10.1053/j.ajkd.2015.07.015
  2. Ikizler, T. A., Burrowes, J. D., Byham-Gray, L. D., Campbell, K. L., Carrero, J. J., Chan, W., Fouque, D., Friedman, A. N., Ghaddar, S., Goldstein-Fuchs, D. J., Kaysen, G. A., Kopple, J. D., Teta, D., Yee-Moon Wang, A., & Cuppari, L. (2020). KDOQI clinical practice guideline for nutrition in CKD: 2020 update. American Journal of Kidney Diseases, 76(3 Suppl 1), S1–S107. https://doi.org/10.1053/j.ajkd.2020.05.006
  3. Bowry, S. K., Kircelli, F., & Misra, M. (2021). Flummoxed by flux: The indeterminate principles of haemodialysis. Clinical Kidney Journal, 14(Suppl 4), i32–i44. https://doi.org/10.1093/ckj/sfab182
  4. García-Prieto, A., de la Flor, J. C., Coll, E., Iglesias, E., Reque, J., & Valga, F. (2023). Expanded hemodialysis: What's up, Doc? Clinical Kidney Journal, 16(7), 1071–1080. https://doi.org/10.1093/ckj/sfad033
  5. Abe, M. (2026). New dialyzer classification in Japan. Contributions to Nephrology, 201, 37–48. https://doi.org/10.1159/000552906
  6. Abe, M., Kikuchi, K., Wada, A., Nakai, S., Kanda, E., & Hanafusa, N. (2024). Current dialyzer classification in Japan and mortality risk in patients undergoing hemodialysis. Scientific Reports, 14(1), 10272. https://doi.org/10.1038/s41598-024-60831-y
  7. Weiner, D. E., Falzon, L., Skoufos, L., Bernardo, A., Beck, W., Xiao, M., & Tran, H. (2020). Efficacy and safety of expanded hemodialysis with the Theranova 400 dialyzer: A randomized controlled trial. Clinical Journal of the American Society of Nephrology, 15(9), 1310–1319. https://doi.org/10.2215/CJN.01210120
  8. Kandi, M., Brignardello-Petersen, R., Couban, R., Wu, C., & Nesrallah, G. (2022). Effects of medium cut-off versus high-flux hemodialysis membranes on biomarkers: A systematic review and meta-analysis. Canadian Journal of Kidney Health and Disease, 9, 20543581211067090. https://doi.org/10.1177/20543581211067090
  9. Kandi, M., Brignardello-Petersen, R., Couban, R., Wu, C., & Nesrallah, G. (2022). Clinical outcomes with medium cut-off versus high-flux hemodialysis membranes: A systematic review and meta-analysis. Canadian Journal of Kidney Health and Disease, 9, 20543581211067087. https://doi.org/10.1177/20543581211067087
  10. Mok, M. M. Y., Yung, S., Kwan, L. P. Y., Yip, T. P. S., Lui, S. L., & Chan, T. M. (2025). Expanded hemodialysis with Theranova compared with conventional high-flux hemodialysis: Prospective randomized 12-month study. Kidney360, 6(7), 1143–1157. https://doi.org/10.34067/KID.0000000769
  11. Lim, J. H., Seo, Y. J., Jeon, Y., Jeon, Y. H., Jung, H. Y., Choi, J. Y., Park, S. H., Kim, C. D., Kang, S. H., Ryu, J. H., Kang, D. H., Cho, J. H., & Kim, Y. L. (2025). Expanded hemodialysis with Theranova dialyzer and residual kidney function in patients starting long-term hemodialysis: A randomized controlled trial. Journal of the American Society of Nephrology, 36(8), 1614–1625. https://doi.org/10.1681/ASN.0000000655
  12. Castillo, J. C., Vesga, J., Rivera, A., Rutherford, P., Sanchez, R., Oliveros, H., Lindholm, B., & Sanabria, M. (2025). Survival differences in patients with high-flux hemodialysis versus expanded hemodialysis: A cohort study. Blood Purification, 54(12), 772–781. https://doi.org/10.1159/000548158
  13. Lee, Y., Jang, M. J., Jeon, J., Lee, J. E., Huh, W., Choi, B. S., Park, C. W., Chin, H. J., Kang, C. L., Kim, D. K., Han, S. S., & Joo, K. W. (2021). Cardiovascular risk comparison between expanded hemodialysis using Theranova and online hemodiafiltration (CARTOON): A multicenter randomized controlled trial. Scientific Reports, 11(1), 10807. https://doi.org/10.1038/s41598-021-90311-6
  14. Gan, L., Gu, L., Ge, Y., Lin, H., Li, Y., Chen, F., Li, W., Gao, B., Ding, F., Zhang, X., Shi, Z., Ji, J., Yao, Q., Keller, B., Sarkar, S., & Zuo, L. (2025). Comparison of middle molecule removal with expanded hemodialysis versus haemodiafiltration among Chinese hemodialysis patients. Renal Failure, 47(1), 2498093. https://doi.org/10.1080/0886022X.2025.2498093
  15. Aktas, O., Akhmedullin, R., Abbay, A., Narin, A. E., Yanilmaz, M. S., Genc, C., Gaipov, A., Covic, A., & Kanbay, M. (2025). Comparative efficacy of expanded hemodialysis and online hemodiafiltration: A systematic review and meta-analysis. International Urology and Nephrology, 57(11), 3761–3772. https://doi.org/10.1007/s11255-025-04559-2
  16. Blankestijn, P. J., Vernooij, R. W. M., Hockham, C., Strippoli, G. F. M., Canaud, B., Hegbrant, J., Barth, C., Covic, A., Cromm, K., Cucui, A., Davenport, A., Rose, M., Török, M., Woodward, M., Bots, M. L., & CONVINCE Scientific Committee Investigators. (2023). Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. The New England Journal of Medicine, 389(8), 700–709. https://doi.org/10.1056/NEJMoa2304820
  17. Vernooij, R. W. M., Hockham, C., Strippoli, G., Green, S., Hegbrant, J., Davenport, A., Barth, C., Canaud, B., Woodward, M., Blankestijn, P. J., Bots, M. L., & CONVINCE Scientific Committee. (2024). Haemodiafiltration versus haemodialysis for kidney failure: An individual patient data meta-analysis of randomised controlled trials. The Lancet, 404(10464), 1742–1749. https://doi.org/10.1016/S0140-6736(24)01859-2
  18. Vernooij, R. W., Strippoli, G. F., Veltkamp, D. M., Nistor, I., Craig, J. C., Saglimbene, V. M., Covic, A. C., & Vecchio, M. (2026). Haemodiafiltration, haemofiltration and haemodialysis for adults with kidney failure. Cochrane Database of Systematic Reviews, 10(10), CD006258. https://doi.org/10.1002/14651858.CD006258.pub3
  19. Battaglia, Y., Shroff, R., Meijers, B., Nistor, I., Alfano, G., Franssen, C., Luyckx, V., Liakopoulos, V., Mantovani, A., Baciga, F., Caccia, F., Momentè, C., Davenport, A., Blankestijn, P. J., Covic, A., Combe, C., & Basile, C. (2025). Haemodiafiltration versus high-flux haemodialysis—A consensus statement from the EuDial Working Group of the ERA. Nephrology Dialysis Transplantation, 40(8), 1590–1614. https://doi.org/10.1093/ndt/gfaf024
  20. Strippoli, G. F. M., Pellegrino, G., Hegbrant, J., Fabbrini, P., Lentini, P. L. M., Aucella, F., Panichi, V., Gallieni, M., Canaud, B., Davenport, A., Ortiz, A., Ramos, R., Malyszko, J., Kazancıoğlu, R., Kuhlman, M., Ferreira, A. C., Cromm, K., Nigwekar, S., Nissenson, A. R., & De Nicola, L. (2026). Online hemodiafiltration for kidney failure: Guidance and best clinical practice recommendations from the Italian Society of Nephrology. Journal of Nephrology. Advance online publication. https://doi.org/10.1093/joneph/aajag225
  21. Bergling, K., & Blankestijn, P. J. (2026). Beyond diffusion: Clinical perspectives on online hemodiafiltration and medium cut-off dialyzers. American Journal of Kidney Diseases, 88(2), 315–322. https://doi.org/10.1053/j.ajkd.2025.11.018
  22. Penny, J. D., Gozdzik, D., Tamasi, T., Dorie, J., Koyle, K., Lozon, Z. B., Cesario, R., Nesrallah, G., & McIntyre, C. W. (2025). Impact of expanded hemodialysis on subjective experience using dynamic patient-reported outcome measurement tool. Kidney Medicine, 7(12), 101134. https://doi.org/10.1016/j.xkme.2025.101134
  23. Levin Iaina, N., Rotshild, E., Mini Goldberg, S., & Beckerman, P. (2025). Expanded hemodialysis with Theranova 500 improves dialysis adequacy and blunts inflammation: A 24-week quasi-randomized trial. Journal of Clinical Medicine, 14(24), 8853. https://doi.org/10.3390/jcm14248853
  24. Reque Santivañez, J., Vazquez Gomez, M., Bielsa Gracia, S., Quevedo Reina, J. C., Garcia Mendez, I., Sanchez Alvarez, J. E., Collado Boira, E., & Perez-Alba, A. (2026). Expanded home hemodialysis trial: Study design and baseline characteristics of a pragmatic real-world cohort. Blood Purification. Advance online publication, 1–7. https://doi.org/10.1159/000553057
  25. Herič, T., Vivoda, T., Bogataj, Š., Kuzmanovski, A., Osredkar, J., Giebułtowicz, J., & Pajek, J. (2026). Targeting protein-bound uremic toxins: A dual approach with medium cut-off membrane dialysis and a dietary intervention—A randomized controlled study. Journal of Clinical Medicine, 15(9), 3228. https://doi.org/10.3390/jcm15093228
  26. Canaud, B., Davenport, A., Morena-Carrere, M., Amico, M., Molinari, N., & Cristol, J. P. (2025). Continuous beta-2 microglobulin-based clearance highlights superiority of high-dose HDF over high-flux HD in predicting outcomes. Scientific Reports, 15(1), 20421. https://doi.org/10.1038/s41598-025-07497-2
  27. Sanabria, M., Vesga, J., Rivera, A., Rutherford, P., Quitian, H., & Lindholm, B. (2026). Budget impact of expanded hemodialysis versus high-flux hemodialysis using real-world evidence in Colombia. Cost Effectiveness and Resource Allocation, 24(1). https://doi.org/10.1186/s12962-026-00754-9
  28. U.S. Food and Drug Administration (FDA). (2020). De Novo classification request for Theranova dialyzers (Theranova 400, Theranova 500): Decision summary DEN190042. Center for Devices and Radiological Health. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN190042.pdf
  29. London Health Sciences Centre Research Institute (LHSCRI). (2024). DIALysis with EXpanded solute removal (DIALEX): A large, simple randomized trial to evaluate the major health effects of expanded versus conventional hemodialysis (ClinicalTrials.gov Identifier NCT06660277). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT06660277
  30. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). (2026). Impact of expanded hemodialysis prescription on global uremic toxin removal compared with high-volume online hemodiafiltration (REMOV-HDx) (ClinicalTrials.gov Identifier NCT07348536). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT07348536
  31. Philippine Health Insurance Corporation (PHIC). (2025, March 27). PhilHealth's expanded benefits bring financial relief to dialysis patients [News release]. https://www.philhealth.gov.ph/news/up/article/2025/news_67e9e793775ed.php
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save